» Articles » PMID: 31061067

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy

Abstract

Purpose: Hormone receptor-positive/HER2-negative (HR/HER2) breast cancer is associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, and demonstrates poor responses to checkpoint inhibitor therapy. Evaluating the effect of standard chemotherapy on the immune microenvironment may suggest new opportunities for immunotherapy-based approaches to treating HR/HER2 breast tumors.

Experimental Design: HR/HER2 breast tumors were analyzed before and after neoadjuvant chemotherapy. sTIL were assessed histologically; CD8 cells, CD68 cells, and PD-L1 staining were assessed immunohistochemically; whole transcriptome sequencing and panel RNA expression analysis (NanoString) were performed.

Results: Ninety-six patients were analyzed from two cohorts ( = 55, Dana-Farber cohort; = 41, MD Anderson cohort). sTIL, CD8, and PD-L1 on tumor cells were higher in tumors with basal PAM50 intrinsic subtype. Higher levels of tissue-based lymphocyte (sTIL, CD8, PD-L1) and macrophage (CD68) markers, as well as gene expression markers of lymphocyte or macrophage phenotypes (NanoString or CIBERSORT), correlated with favorable response to neoadjuvant chemotherapy, but not with improved distant metastasis-free survival in these cohorts or a large gene expression dataset ( = 302). In paired pre-/postchemotherapy samples, sTIL and CD8 cells were significantly decreased after treatment, whereas expression analyses (NanoString) demonstrated significant increase of multiple myeloid signatures. Single gene expression implicated increased expression of immunosuppressive (M2-like) macrophage-specific genes after chemotherapy.

Conclusions: The immune microenvironment of HR/HER2 tumors differs according to tumor biology. This cohort of paired pre-/postchemotherapy samples suggests a critical role for immunosuppressive macrophage expansion in residual disease. The role of macrophages in chemoresistance should be explored, and further evaluation of macrophage-targeting therapy is warranted.

Citing Articles

Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer.

Garber H, Basu S, Jindal S, He Z, Chu K, Raghavendra A Oncotarget. 2024; 15:238-247.

PMID: 38502947 PMC: 10950364. DOI: 10.18632/oncotarget.28567.


Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy.

Arqueros C, Gallardo A, Vidal S, Osuna-Gomez R, Tibau A, Lidia Bell O Int J Mol Sci. 2024; 25(5).

PMID: 38473874 PMC: 10932208. DOI: 10.3390/ijms25052627.


Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy.

Yin G, Liu L, Yu T, Yu L, Feng M, Zhou C Genome Med. 2024; 16(1):11.

PMID: 38217005 PMC: 10787499. DOI: 10.1186/s13073-024-01286-8.


A comprehensive review on the applications of ferrite nanoparticles in the diagnosis and treatment of breast cancer.

Akhtar M, Afzaal A, Saleem A, Roheel A, Khan M, Imran M Med Oncol. 2024; 41(2):53.

PMID: 38198041 DOI: 10.1007/s12032-023-02277-2.


Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.

Gao H, Ouyang D, Guan X, Xu J, Chen Q, Zeng L BMC Cancer. 2024; 24(1):50.

PMID: 38195475 PMC: 10775541. DOI: 10.1186/s12885-024-11815-8.


References
1.
Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G . The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006; 8(3):190-8. PMC: 1578520. DOI: 10.1593/neo.05733. View

2.
Fraser Symmans W, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-22. DOI: 10.1200/JCO.2007.10.6823. View

3.
Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G . The anticancer immune response: indispensable for therapeutic success?. J Clin Invest. 2008; 118(6):1991-2001. PMC: 2396905. DOI: 10.1172/JCI35180. View

4.
Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

5.
Denkert C, Loibl S, Noske A, Roller M, Muller B, Komor M . Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2009; 28(1):105-13. DOI: 10.1200/JCO.2009.23.7370. View